# Nanjing Sanhome Pharmaceutical, Co., Ltd. trials: 23 (2026)

ClinicalTrials.gov lists 23 trials with Nanjing Sanhome Pharmaceutical, Co., Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Nanjing Sanhome Pharmaceutical, Co., Ltd.: 23 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/nanjing-sanhome-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 29, 2026 | NCT07557004 | A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Active not recruiting | HR+ / HER2- Advanced Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557004) |
| February 6, 2026 | NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2/3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392866) |
| February 5, 2026 | NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Recruiting | Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390838) |
| January 23, 2026 | NCT07362264 | A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Active not recruiting | Liver Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362264) |
| October 12, 2023 | NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06080776) |
| August 20, 2021 | NCT05015309 | A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Advanced Malignant Tumor | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05015309) |
| April 13, 2021 | NCT04843033 | A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04843033) |
| March 23, 2021 | NCT04810533 | The Absorption, Metabolism and Excretion of \[14C\]SH-1028 in Chinese Healthy Male Volunteers | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Completed | Healthy Male Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04810533) |
| March 22, 2021 | NCT04808648 | The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Healthy Male Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04808648) |
| March 19, 2021 | NCT04806659 | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Acute Myelogenous Leukemia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04806659) |
| July 14, 2020 | NCT04470141 | A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 | Unknown | Peripheral T Cell Lymphoma | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04470141) |
| June 16, 2020 | NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 | Unknown | Follicular Lymphoma(FL), Marginal Zone Lymphoma(MZL) | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04431089) |
| June 9, 2020 | NCT04423380 | A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04423380) |
| January 27, 2020 | NCT04239833 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 3 | Unknown | Non-Small Cell Lung Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04239833) |
| August 28, 2019 | NCT04070235 | SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2/3 | Unknown | Hepatitis C, Chronic | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04070235) |
| July 5, 2019 | NCT04006860 | A Food-Effect Study of SHC014748M in Healthy Subjects | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Healthy Volunteer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04006860) |
| June 4, 2019 | NCT03973632 | Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Healthy Volunteer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03973632) |
| January 30, 2019 | NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 | Unknown | Non-Small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03823807) |
| November 21, 2018 | NCT03748745 | A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Completed | Drug Interactions | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03748745) |
| August 7, 2018 | NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Advanced Solid Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03618043) |
| July 27, 2018 | NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Non-small Cell Lung Cancer | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03603262) |
| July 17, 2018 | NCT03588923 | Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Completed | HCV Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03588923) |
| July 17, 2018 | NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Unknown | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03588598) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 15 |
| Completed | 3 |
| Recruiting | 2 |
| Active not recruiting | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Liver Neoplasms | 2 |
| Hepatitis C | 2 |
| Neoplasm Metastasis | 1 |
| Lung Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Hepatitis C, Chronic | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Carcinoma, Hepatocellular | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Spanish restaurants in the United States](https://specstream.ai/data/businesses/spanish-restaurants/united-states)
- [Structural engineering firms in the United States](https://specstream.ai/data/businesses/structural-engineering-firms/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
